Cancer- and treatment-related anemia: Clinical Practice Guidelines in Oncology

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue 6, 2005, Pages 772-789

  Rodgers III, George M ^a   Cella, David ^b   Chanan Khan, Asher ^c   Chesney, Carolyn ^d   Cleeland, Charles ^e   Coccia, Peter F ^f   Demetri, George D ^g   Djulbegovic, Benjamin ^h   Garst, Jennifer L ⁱ   Gore, Margaret ^d   Kraut, Eric H ^j   Lin, Weei Chin ^k   Millenson, Michael ^l   Mock, Victoria ^m   Reinke, Denise ⁿ   Rosenthal, Joseph ^o   Sabbatini, Paul ^p  

^a UNIVERSITY OF UTAH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NEBRASKA MEDICAL CENTER   (United States)

^f Dana Farber/Partners CancerCare   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h DUKE CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l FOX CHASE CANCER CENTER   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^o City of Hope Cancer Center   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Anemia; Chemotherapy; Darbapoetin; Epoetin; Erythropoietin; Ferric gluconate; Heme iron polypeptide; Hemoglobin; Iron dextran; Iron sucrose; NCCN Clinical Practice Guidelines in Oncology; Quality of life; Serum ferritin

Indexed keywords

CARBOPLATIN; ERYTHROPOIETIN; FERRITIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; TOPOTECAN; TRANSFERRIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; HEMOGLOBIN;

ANEMIA; APLASIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; HYPERTENSION; IRON THERAPY; META ANALYSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SEIZURE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; ARTICLE; BLOOD; FORECASTING; INCIDENCE; METABOLISM; NEOPLASM; PRACTICE GUIDELINE;

ANEMIA; BLOOD TRANSFUSION; CLINICAL TRIALS; ERYTHROPOIETIN; FORECASTING; GUIDELINES; HEMATINICS; HEMOGLOBINS; HUMANS; INCIDENCE; NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33644824195     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2005.0046     Document Type: Review

References (33)

1. Groopman JL, Itri L. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Harrison LB, Shasha D, White C, et al. Radiotherapy-associated anemia: the scope of the problem. Oncologist 2000;5[suppl 2]:1-7.
3. Henry DH. Supplemental iron: a key to optimizing the response of cancer related anemia to rHuEPO. Oncologist 1998;3:275-278.
4. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1609-1692.
5. Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, douhle blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
6. Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-1214.
7. Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
8. Vansteenkiste J, Pirker R, Massuti B, et al. Double blind, placebo controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
9. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
10. Glaspy JA, Tchekmedyian NS. Darbepoetin alfa administered every two weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002;16(suppl 11):23-29.
11. Mirtsching M, Charu V, Vadhan-Raj S, et al. Every two week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy induced anemia. Results of combined analysis. Oncology 2002;16(suppl 11):31-36.
12. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-458.
13. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002;11:207-221.
14. Demetri GD, Kris M, Wade J, et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
15. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoeitin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
16. Crawford J, Cella D, Cleeland C, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
17. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
18. Grogan M, Thomas GM, Melmed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
19. Obermair A, Cheuk R, Horwood K, et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: preliminary results. Cancer 2001;15:903-908.
20. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996;201:553-558.
21. Kumar P, Wan J, Viera F. Analysis of survival outcome and prognostic factors (PF) in the treatment of unresectable head and neck (H/N) squamous cell carcinoma (SCCa) using supra-dose intra-arterial targeted cisplatin and concurrent radiotherapy [abstract]. Proc ASCO 1997;16:390a.
22. Henke M, Laszig R, Rube C, et al. Erythropoetin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double blind, placebo controlled trial. Lancet 2003;362:1255-1260.
23. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 2005;129:206-209.
24. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982;60:1241-1246.
25. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
26. Cleeland CS, Wang XS. Measuring and understanding fatigue. Oncology 1999;13:91-97.
27. Hensley ML, Lebeau D, Leon LF, et al. Identification of risk factors for requiring transfusion during front line chemotherapy for ovarian cancer. Gynecol Oncol 2001;81:485-489.
28. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist 2004;9:696-707.
29. Waltzman RJ, Fesen M, Justice GR, et al. Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 meg Q2W in anemic cancer patients receiving chemotherapy: preliminary results of a comparative trial. ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 2004;22(suppl 14):8153.
30. Auerbach M, Ballard H, Trout RJ, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
31. Nissenson AR, Berns JS, Sakiewicz P, et al. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003;42:325-330.
32. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000;13:381-384.
33. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.